VSC Share Price Performance
€0.10
-4.20 (-97.67%)
Price €0.10
Share Pricen/a
4SC (FRA:VSC) Is Carrying A Fair Bit Of Debt
Oct 15
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 0 Fair Values set on narratives written by author
VSC Community Narratives
There are no narratives available yet.
There are no community narratives available.
Trending Discussion
Recently Updated Narratives
No recently updated narratives available.
Snowflake Analysis
4SC AG Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
- -0.70
- 78.71%
- -3,800.50%
- 0%
About VSC
- Founded
- 1997
- Employees
- 14
- CEO
- WebsiteView website
4SC AG, a biopharmaceutical company, engages in developing small-molecule drugs that address cancer diseases with high unmet medical needs in Germany and internationally. The company develops Resminostat, an orally administered histone deacetylase inhibitor for the treatment of cutaneous T-cell lymphoma. It also out-licenses and partnered drug candidates to pharma and biotech companies. The company was founded in 1997 and is headquartered in Planegg, Germany.
